HomepageEarnings Events Newsdesk 55 minutes ago Roivant Sciences (ROIV) Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release Roivant Sciences (ROIV) Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) » « Cognizant Technology Solutions Corporation (CTSH) Cognizant appointed by the UK Government as a strategic industry partner to its TechFirst programme Newsdesk:
